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Coronary Revascularization
for Patients With Diabetes
Updated Data Favor
Coronary Artery Bypass Grafting*
Stephen G. Ellis, MD
Cleveland, Ohio
Diabetes mellitus, by virtue of myriad processes, including
its effects reducing vascular nitric oxide and prostacyclin
production and increasing endothelin, angiotensin II, tissue
factor activity, and platelet activity (1,2), wreaks havoc on
coronary and other arteries, leading to diffuse and often
unstable coronary atherosclerosis. It is also a risk factor for
poor outcomes after both percutaneous coronary interven-
tion (PCI) and coronary artery bypass grafting (CABG) (3).
Numerous randomized controlled trials have compared
outcomes after PCI and CABG in patients with diabetes.
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Many observational studies on the same topic have also been
published, but they are difficult to interpret because of
inherent biases (patients were referred to one or another
treatment for a reason, and outcomes were better when
physicians chose revascularization strategies than when
patients were randomized in the Bypass Angioplasty Revas-
cularization Investigation trial) (4). In 2009, Hlatky et al.
(5) summarized the results of randomized controlled trials
in a meta-analysis of 10 randomized trials from the balloon
angioplasty and bare-metal stent era. In 1,233 patients with
diabetes, 8-year mortality rates were significantly lower with
CABG, 22% versus 34%, and there was a significant
statistical interaction in the entire 7,812-patient analysis for
mortality between diabetes and form of revascularization
(p  0.014) (5).
Since then, drug-eluting stents and newer forms of anti-
platelet therapy have been introduced, and surgical techniques
have been refined. In addition, long-term follow-up of 2 major
relevant comparative trials, SYNTAX (Synergy Between Per-
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contents of this paper to disclose.cutaneous Coronary Intervention With Taxus and Cardiac
Surgery) and CARDIA (Coronary Artery Revascularization in
Diabetes) (6,7), has been completed. The findings of a further
trial, VA CARDS (Veterans Affairs Coronary Artery Revas-
cularization in Diabetes Study), are reported in this issue of the
Journal (8), and the results of the larger FREEDOM (Future
Revascularization Evaluation in Patients With Diabetes Mel-
litus: Optimal Management of Multivessel Disease) trial were
just presented at the 2012 meeting of the American Heart
Association.
SYNTAX was designed as a noninferiority study with
major adverse cardiac or cerebrovascular events as the
primary study end point, enrolling patients with 3-vessel or
left main coronary artery disease. PCI patients received the
paclitaxel-eluting Taxus stent (Boston Scientific Corpora-
tion, Natick, Massachusetts ). In the entire study after 4
years, both overall and cardiac death were lower in the
CABG than the PCI group (8.8% vs. 11.7%, p  0.048,
and 4.3% vs. 7.6%, p  0.004, respectively). Differences
were driven primarily by results from patients with SYNTAX
scores  22.
Patients with diabetes (n 452) were a predefined subset
of interest. Some of the findings are not as well recognized
as they ought to be, as they are available only in supple-
mental online material. At 3 years, major adverse cardiac or
cerebrovascular events occurred in 37.0% and 22.9% of the
PCI and CABG patients with diabetes, respectively (p 
0.002). The composite of death, stroke, or myocardial
infarction (MI), considered by some more relevant because
it excludes the less impactful target vessel revascularization,
occurred in 16.3% and 14.0% of the PCI and CABG
patients, respectively (p  0.53). Death occurred in 13.6%
and 8.7% of the PCI and CABG patients, respectively
(p  0.11). From the vantage point of PCI, patients with
diabetes requiring insulin fared particularly poorly, with
cardiac death occurring in 12.6% compared with 4.5%
with CABG (p 0.06) and the composite of death, stroke,
and MI occurring in 22.7% compared with 13.6% with
CABG (p  0.11). Differences for patients requiring only
oral hypoglycemic agents were much more modest, 11.5%
versus 8.4% and 12.2% versus 14.2%, respectively. One year,
but not 3-year, results by SYNTAX score have also been
reported (9). In that analysis, rates of major adverse cardiac
and cerebrovascular events were higher with PCI than
CABG for scores  22, but this was driven primarily by
differences in rates of target vessel revascularization, and
there was no apparent relationship between SYNTAX
scores and the outcomes of PCI versus CABG for the end
point of stroke or MI. There was, however, a significant
apparent difference in mortality rates for patients with
SYNTAX scores 32, favoring CABG, 4.1% versus 13.5%
(p  0.04). Given the large number of subset comparisons
in SYNTAX, one must be cautious, however, not to overinter-
pret the meaning of a low p value, as the opportunity for
spurious findings is high.
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CABG in the current era was the CARDIA trial, enrolling
510 patients with proximal complex left anterior descending
coronary artery or multivessel disease between 2002 and
2007. One-year results have been published (7), and the
5-year data were recently presented at the European Society
of Cardiology (Kevin J. Beatt, MD, slides and personal
communication, 2012). Seventy-one percent of PCI-treated
patients received sirolimus-eluting stents, and 29% received
bare-metal stents. This was designed as a noninferiority trial
with the primary outcome of the composite of death, MI,
and stroke. Criteria for PCI noninferiority were not met.
Long-term rates for the PCI and CABG cohorts for the
primary end point were 26.6% and 20.5%, respectively
(p  0.11). Rates for death were 14.0% and 12.6%,
respectively (p  0.53). Significant differences were seen for
the end points of nonfatal MI (14.0% vs. 6.3%, p  0.007)
and repeat revascularization (21.9% vs. 8.3%, p 0.001) for
the PCI and CABG groups, respectively. Only 1-year
outcomes for the insulin-dependent and non-insulin-dependent
subgroups have been reported, and there are no data
available by SYNTAX score as of yet. At 1 year, the primary
outcome in the insulin-dependent cohorts tended to be
worse for PCI compared with CABG (17.4% vs. 10.3%),
but the interaction p value did not approach statistical
significance.
The results of the 1,900-patient FREEDOM trial have
yet to be fully digested but seem to show a clear benefit from
CABG in patients with diabetes with predominantly
3-vessel disease, regardless of SYNTAX score.
It is important to assess the consistency of results across
trials and venues. The findings of the VA CARDS study,
comparing PCI and CABG results in patients with diabe-
tes, with either single-vessel proximal left anterior descend-
ing coronary artery or multivessel left anterior descending
coronary artery disease, published herein (8) are consistent
with the results of these other trials but raise a number of
questions. First, in an incomplete and underpowered study
in which death was not the primary end point and in which
there was a nearly statistically significant imbalance in initial
left ventricular function favoring CABG, how should one
interpret the “statistically significant” difference in mortality
at 2 years in this study favoring CABG, 5.0% versus 21.0%
(p 0.02)? Acknowledging the small number of events, one
must recognize that this apparent difference may be due to
the play of chance. It would have been useful if the investiga-
tors had provided the causes of death for these patients. That
said, and considering at last count from these 4 relatively
contemporary trials that there were 159 deaths in the CABG
groups and 244 deaths in the PCI groups, one cannot ignore
these findings.
Second, how should one interpret the higher rate of
nonfatal MI in the CABG group, particularly considering
the novel definition used in the study? Most trials in this
field define periprocedural PCI infarction as creatine kinase-MB
elevation 3 times the upper limit of normal and requireenzyme elevation or Q waves on electrocardiography to
define late MI. In this study, periprocedural MI required
creatine kinase-MB elevation  5 times the upper limit of
normal, and the finding of a fixed 20% myocardial
perfusion defect detected during annual nuclear studies was
also considered an MI. Thus, in this study, some events that
might be considered periprocedural PCI MIs were missed.
The appropriate definition of periprocedural PCI infarction
is highly debated at present, however. Late fixed perfusion
defects predominated in the CABG group. The meaning of
this finding, which may have been due to severe bypass graft
narrowing or MI, is not clear. Use of more traditional
definitions in this study would have led to the conclusion
that CABG was superior to PCI.
Third, why, particularly when the Veterans Affairs (VA)
system has contributed many important randomized trials in
the field of coronary artery disease, dating from the original
VA Cooperative Bypass Surgery trial and extending more
recently to studies such as the Veterans Affairs Non-Q-
Wave Infarction Strategies In-Hospital and Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation trials, could the VA system not complete such an
important study? Many have recognized the increasing
difficulty of performing randomized controlled trials in
United States, often due to stifling regulations and cost, but
one would have thought that perhaps the VA system would
be less subject to these issues. The report provides inade-
quate information to answer this question, but VA leader-
ship should carefully consider why this important study
could not be completed.
Fourth, and possibly related to the third question, how
can one explain the diminutive percent of angiographically
eligible patients screened in this study? Only 9% of patients
with diabetes undergoing clinically indicated catheterization
were angiographically eligible in the study. Using the Cleve-
land Clinic database (2010 to present) as a comparator and
using a more stringent definition (excluding stenoses 70%),
we would have estimated that 31% of patients with diabetes
would have been eligible.
Amalgamating these data, a logical conclusion appears to
be that because CABG excludes longer segments of coro-
nary arteries than PCI treats, hence potentially exposing
patients with diabetes to lesser risk for clinically important
plaque progression, it produces superior outcomes. Perhaps
someday, more powerful lipid-lowering agents (e.g.,
PCSK9 inhibitors) may minimize this risk to the extent that
only severe lesions rather than severely atherosclerotic seg-
ments will need to be revascularized in patients with
diabetes with angina. Until then, it seems, on the basis of
the current body of evidence, that CABG should be
preferred over PCI in patients with diabetes and multivessel
disease with complex anatomy exemplified by SYNTAX
scores  22, and perhaps even all patients with diabetes with
multivessel disease. That said, we still need further data
regarding the important interaction between lesion number
and complexity and clinical outcomes with the 2 approaches.
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terns and values. The best recommendations will contextualize
an individual’s needs relative to the body of data generally
favoring surgery.
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